Click on headlines below to download research

Next step US Feraccru approval
Shield Therapeutics | 03/04/2019

Shield Therapeutics reported FY18 results in line with our expectations. Total revenue of £11.9m included the £11.0m upfront payment from European…

Executive interview - Shield Therapeutics
Executive interview - Shield Therapeutics | 25/03/2019

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom that listed on AIM in 2016. Its primary focus is…

Feraccru performs again in a Phase III study
Shield Therapeutics | 04/03/2019

Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-approved oral formulation of iron positioned…

Fortified for growth
Shield Therapeutics | 19/02/2019

Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment…